Gregg Sherman, MD
Northwest Heart and Heath
Harvey C. Parker, Ph.D., CCMEP
National Association for Continuing Education
Joshua Kilbridge, President
San Francisco, CA
Acute coronary syndrome (ACS), a potentially life-threatening form of coronary artery disease (CAD), accounts for over 1.4 million hospital admissions in the United States every year. About 9-19% of ACS patients die in the first 6 months after diagnosis, with about one-half of these deaths occurring within 30 days of diagnosis. Manifestations of ACS include unstable angina, acute myocardial infarction (ST-segment elevation MI [STEMI] and non-STEMI [NSTEMI]), and sudden cardiac death. Risk estimation is important for optimal patient care in ACS and risk assessment tools such as the TIMI and GRACE algorithms can assist in assessing the risk of death and ischemic events, thereby providing a basis for therapeutic decision making.
The management of ACS aims at immediate relief of ischemia, reduction in the size of infarct, and prevention of serious adverse events, including death, (recurrent) MI or severe ischemia, and arrhythmias. Antithrombotic therapies for patients with definite ACS include aspirin, thienopyridines, unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH), glycoprotein IIb/IIIa receptor antagonists and newer antiplatelet agents, antithrombins and fibrinolytics, and invasive therapies. Knowledge of specific drugs for acute, and long-term, management is important for optimizing the risk-benefit ratio.
This program will help to bridge the knowledge and performance gaps related to identification, risk stratification, and management of ACS as well as patient communication strategies. There are two activities in this curriculum. Each activity in the series will begin with a brief didactic topic overview followed by two “Patient Continua,” each consisting of the presentation of a patient’s interaction with health care team over a period of time. The patients selected for these continua will all have different presentations and different outcomes. This approach will allow for the curriculum to address four different patient presentations and fully address assessment, diagnosis, initial management, and follow-up management.
DISCLOSURE POLICY STATEMENT:
It is the policy of NACE to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. NACE assesses conflict of interest with its faculty, planners and managers of CME activities. Conflicts of interest that are identified are resolved by reviewing that presenter's content for fair balance and absence of bias, scientific objectivity of studies utilized in this activity, and patient care recommendations.
While NACE endeavors to review faculty content, it remains the obligation of each physician or other healthcare practitioner to determine the applicability or relevance of the information provided from this course in his or her own practice.
DISCLOSURE OF CONFLICTS OF INTEREST:
William H. Matthai, Jr., MD, FACC, Course Director, has the following relationships to disclose: Investigator Medicor International, Johnson & Johnson and AstraZenca.
Carl R. Reynolds, M.D., FACC, faculty, has no real or apparent conflicts of interest to report.
Valerian L. Fernandes, MD, MRCP, FACC faculty, has no real or apparent conflicts of interest to report.
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.
Harvey Parker, PhD, has no real or apparent conflicts of interest to report.
Josh Kilbridge has no real or apparent conflicts of interest to report.
DISCLOSURE OF UNLABELED USE:
NACE requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
The opinions expressed during the educational activity are those of the faculty and do not necessarily represent the views of NACE. The information is presented for the purpose of advancing the attendees' professional development.
The National Association for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. AANP Provider Number 121222.
This CME activity was planned and produced in accordance with the ACCME Essentials and the AANP CE Standards and Policies and AANP Commercial Support Standards.
For CME questions, please contact: NACE at firstname.lastname@example.org
Contact this CME provider for privacy and confidentiality policy statement information at:
CREDIT DESIGNATION STATEMENT:
NACE designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim credit commensurate with the extent of their participation in the activity.
National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Academy of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 hrs contact hours of continuing education (which includes 0.5 hour of pharmacology credit)
TO OBTAIN CME CREDITS:
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit.
- Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
- You must score 60% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
COURSE FORMAT/MEDIUM: Internet CME Activity
ESTIMATED TIME TO COMPLETE: 60 minutes
This activity is sponsored by National Association for Continuing Education.
This educational activity is supported by an educational grant from Daiichi Sankyo, Inc., and Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com.
If you have any questions regarding this activity, send an email to email@example.com.
Copyright © 2014 National Association for Continuing Education. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of NACE is prohibited.